A continued study in patients with Hematologic Cancers previously treated with Tafasitamab.

Phase 1

Recruiting

• Conditions: Hematologic malignancies; MedDRA version: 21.1Level: LLTClassification code: 10066481Term: Hematological malignancy Class: 10029104; Therapeutic area: Diseases [C] - Neoplasms [C04]

• Registration Number: CTIS2022-500765-27-00
• Lead Sponsor: Morphosys AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-07-01
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol., Having been enrolled and is still receiving treatment with tafasitamab at the end of a MorphoSys/Incyte-sponsored clinical study., Is tolerating tafasitamab treatment at the dose specified in the parent protocol as assessed by the Investigator., Is in complete/partial response or stable disease and is receiving clinical benefit from treatment with tafasitamab in the parent study, as assessed by the Investigator., Has demonstrated compliance, as assessed by the Investigator, with the parent protocol requirements., Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures indicated in this protocol.

Exclusion Criteria

Patient who is legally institutionalized, or under judicial protection., Has met one or more criteria for permanent tafasitamab treatment discontinuation as stipulated in the parent protocol., Able to access tafasitamab outside a clinical study., Patient with an uncontrolled intercurrent illness or any concurrent condition that, in the Investigator’s opinion, would jeopardize the safety of the patient or compliance with the protocol., A female patient who is pregnant confirmed by a pregnancy test prior to enrollment, breastfeeding, or a woman of childbearing potential (WOCBP) (as defined in Appendix 5: Contraceptive Guidance and Collection of Pregnancy Information) who does not agree to follow the contraceptive guidance in Appendix 5: Contraceptive Guidance and Collection of Pregnancy Information during the treatment period and for at least 3 months after the last dose of study treatment, and does not refrain from donating oocytes during this period., A male patient who does not agree to use contraception as detailed in Appendix 5: Contraceptive Guidance and Collection of Pregnancy Information during the treatment period and for at least 3 months after the last dose of study treatment (if they have a heterosexual partner who is a woman of childbearing potential) and who does not refrain from donating sperm during this period.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified